Published in Pharmacogenetics on August 01, 1999
Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol (2005) 0.88
The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6. Eur J Clin Pharmacol (2007) 0.83
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther (2007) 4.33
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 4.04
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther (2011) 3.09
Validity of cardiovascular disease risk factors assessed by telephone survey: the Behavioral Risk Factor Survey. J Clin Epidemiol (1993) 2.91
Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy. J Clin Psychiatry (1999) 2.61
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther (2013) 2.38
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther (2008) 2.31
Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther (2007) 2.17
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics (2000) 2.17
Reliability and changes in validity of self-reported cardiovascular disease risk factors using dual response: the behavioral risk factor survey. J Clin Epidemiol (1996) 2.11
Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis (1993) 2.10
Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature (1990) 1.96
Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations. Clin Pharmacokinet (1992) 1.94
Pediatric acetaminophen overdose: risk factors associated with hepatocellular injury. Arch Pediatr Adolesc Med (2000) 1.80
Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet (1999) 1.79
Relative abundance of organochlorine pesticides and polychlorinated biphenyls in adipose tissue and serum of women in Long Island, New York. Cancer Epidemiol Biomarkers Prev (1998) 1.77
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother (1999) 1.77
Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet (1999) 1.67
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics (1998) 1.64
Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol (1991) 1.57
Acute hepatic failure associated with the use of sodium valproate. N Engl J Med (1979) 1.55
Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness? Clin Infect Dis (1998) 1.52
Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. Clin Pharmacol Ther (2008) 1.48
Clinical pharmacology: a discipline called to action for maternal and child health. Clin Pharmacol Ther (2007) 1.46
Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension. JPEN J Parenter Enteral Nutr (1991) 1.44
Outcomes of weight-based heparin dosing based on literature guidelines and institution individualization. Pharmacotherapy (2000) 1.39
Application of pharmacokinetics in the diagnosis of chemical abuse in Münchausen syndrome by proxy. Clin Pediatr (Phila) (1988) 1.38
Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics (1999) 1.36
Acetaminophen overdose with therapeutic intent. J Pediatr (1998) 1.29
Immediate action needed to improve labeling of prescription drugs for pediatric patients. Ann Pharmacother (1997) 1.25
Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther (2008) 1.22
Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther (1999) 1.22
Human acetyltransferase polymorphisms. Mutat Res (1997) 1.21
Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med (2000) 1.21
Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis. Antimicrob Agents Chemother (1985) 1.20
Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother (1997) 1.20
Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr (1982) 1.19
Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls. Clin Pharmacol Ther (2007) 1.18
Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos (1992) 1.17
Treatment of neonatal hypertension with enalaprilat. J Pediatr (1990) 1.17
Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother (1995) 1.15
Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol Genet Metab (2008) 1.13
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther (2000) 1.12
Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am (1997) 1.12
Efficacy, disposition and pharmacodynamics of aspirin, acetaminophen and choline salicylate in young febrile children. Ther Drug Monit (1982) 1.12
Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci (2000) 1.11
Single-dose, placebo-controlled comparative study of ibuprofen and acetaminophen antipyresis in children. J Pediatr (1991) 1.10
The absolute bioavailability of oral melatonin. J Clin Pharmacol (2000) 1.09
Single-dose pharmacokinetics of ibuprofen and acetaminophen in febrile children. J Clin Pharmacol (1992) 1.06
Use of a microplate reader in an assay of glutathione reductase using 5,5'-dithiobis(2-nitrobenzoic acid). Anal Biochem (1989) 1.05
Treatment of pain with gabapentin in a neonate. Pediatrics (2001) 1.05
Bendectin: the wrong way to regulate drug availability. Can Med Assoc J (1983) 1.04
Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr (1984) 1.04
Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther (1984) 1.03
NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics (1998) 1.03
The neurotoxicity of cyclotrimethylenetrinitramine (RDX) in a child: a clinical and pharmacokinetic evaluation. J Toxicol Clin Toxicol (1986) 1.01
Crystal structure of human catecholamine sulfotransferase. J Mol Biol (1999) 1.01
Cocaine: clinical pharmacology and toxicology. J Pediatr (1989) 1.01
Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother (2006) 1.01
Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos (1999) 0.99
Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther (1998) 0.99
Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions. Antimicrob Agents Chemother (1997) 0.98
Measurement of acetaminophen-protein adducts in children and adolescents with acetaminophen overdoses. . J Clin Pharmacol (2001) 0.98
Factors affecting aminoglycoside disposition: effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics. Clin Pharmacol Ther (1986) 0.98
Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy (2001) 0.98
The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res (1997) 0.98
Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther (2001) 0.97
Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol (2002) 0.96
Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. J Clin Pharmacol (2001) 0.96
Self-reported physical activity in a rural county: a New York county health census. Am J Public Health (1994) 0.96
Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet (1998) 0.96
Single daily dose of aminoglycosides--a concept whose time has not yet come. Clin Infect Dis (1997) 0.95
Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother (1998) 0.95